| Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. | 2022 | The Lancet |
| Association of novel androgen receptor axis-targeted therapies with diarrhea in patients with prostate cancer: a Bayesian network analysis. | 2022 | Frontiers in Medicine |
| Comparison of treatments for nonmetastatic castration-resistant prostate cancer: matching-adjusted indirect comparison and network meta-analysis. | 2022 | Journal of the National Cancer Institute |
| A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents. | 2022 | Anti-Cancer Drugs |
| Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: a systematic review. | 2022 | Urologic Oncology: Seminars and Original Investigations |
| Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis. | 2021 | Prostate Cancer and Prostatic Diseases |
| Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile: an updated systematic review and meta-analysis. | 2021 | Minerva Urology and Nephrology |
| Novel androgen receptor inhibitors in non-metastatic, castration-resistant prostate cancer: a systematic review and network meta-analysis. | 2021 | Frontiers in Oncology |
| Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: a systematic review. | 2021 | Journal of Geriatric Oncology |
| Efficacy and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. | 2021 | Frontiers in Oncology |
| Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. | 2021 | Prostate Cancer and Prostatic Diseases |
| Apalutamide, enzalutamide, and darolutamide for non‑metastatic castration‑resistant prostate cancer: a systematic review and network meta‑analysis. | 2020 | International Journal of Clinical Oncology |
| Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. | 2020 | European Urology |
| Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. | 2020 | Prostate Cancer and Prostatic Diseases |
| A systematic review and network meta-analysis of novel androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer. | 2020 | Clinical Genitourinary Cancer |
| Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. | 2020 | Journal of Oncology Pharmacy Practice |
| Systemic management for non-metastatic castration-resistant prostate cancer. | 2020 | American Journal of Clinical Oncology |
| Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. | 2020 | Prostate Cancer and Prostatic Diseases |
| Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration resistant prostate cancer: a systematic review and meta-analysis. | 2020 | Journal of Pharmacy and Pharmaceutical Sciences |
| Comparative efficacy of combined radiotherapy, systemic therapy, and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a network meta-analysis and systematic review. | 2020 | Frontiers in Oncology |
| Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer. | 2019 | Medicine |
| Third-line treatment and 177Lu-PSMA radio ligand therapy of metastatic castration-resistant prostate cancer: a systematic review. | 2018 | European Journal of Nuclear Medicine and Molecular Imaging |
| Systematic review and network meta-analysis of treatments for chemotherapy-naive patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer. | 2018 | Value in Health |
| Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration‑resistant prostate cancer: a systematic review. | 2017 | Asian Journal of Andrology |
| Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature. | 2017 | Current Medical Research and Opinion |
| First‐line non‐cytotoxic therapy in chemotherapy‐naive patients with metastatic castration‐resistant prostate cancer: a systematic review of 10 randomised clinical trials. | 2017 | BJU International |
